Your browser doesn't support javascript.
loading
Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children.
Whangbo, Jennifer S; Kim, Haesook T; Mirkovic, Nikola; Leonard, Lauren; Poryanda, Samuel; Silverstein, Sophie; Kim, Soomin; Reynolds, Carol G; Rai, Sharmila C; Verrill, Kelly; Lee, Michelle A; Margossian, Steven; Duncan, Christine; Lehmann, Leslie; Huang, Jennifer; Nikiforow, Sarah; Alyea, Edwin P; Armand, Philippe; Cutler, Corey S; Ho, Vincent T; Blazar, Bruce R; Antin, Joseph H; Soiffer, Robert J; Ritz, Jerome; Koreth, John.
Afiliación
  • Whangbo JS; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Kim HT; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Mirkovic N; Harvard Medical School, Boston, MA.
  • Leonard L; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA.
  • Poryanda S; Harvard School of Public Health, Boston, MA.
  • Silverstein S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
  • Kim S; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Reynolds CG; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Rai SC; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
  • Verrill K; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Lee MA; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Margossian S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
  • Duncan C; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
  • Lehmann L; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston MA.
  • Huang J; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Nikiforow S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Alyea EP; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Armand P; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Cutler CS; Harvard Medical School, Boston, MA.
  • Ho VT; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Blazar BR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Antin JH; Harvard Medical School, Boston, MA.
  • Soiffer RJ; Division of Hematology-Oncology, Boston Children's Hospital, Boston, MA.
  • Ritz J; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA.
  • Koreth J; Harvard Medical School, Boston, MA.
Blood Adv ; 3(17): 2550-2561, 2019 09 10.
Article en En | MEDLINE | ID: mdl-31471324
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-2 / Enfermedad Injerto contra Huésped Aspecto: Patient_preference Límite: Adult / Child / Female / Humans / Male Idioma: En Revista: Blood Adv Año: 2019 Tipo del documento: Article País de afiliación: Marruecos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Interleucina-2 / Enfermedad Injerto contra Huésped Aspecto: Patient_preference Límite: Adult / Child / Female / Humans / Male Idioma: En Revista: Blood Adv Año: 2019 Tipo del documento: Article País de afiliación: Marruecos